© Reuters.
Valiant Laboratories, a manufacturer of Paracetamol Active Pharmaceutical Ingredient (API), listed its shares at a premium on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Friday. This follows a highly subscribed Initial Public Offering (IPO), which was oversubscribed 29.76 times.
Valiant Laboratories reported a 16% revenue growth in fiscal 2023. The company plans to use the IPO proceeds for capital expenditure (capex), working capital, and corporate needs. This is in line with InvestingPro Tips’ observation that the company holds more cash than debt on its balance sheet, indicating a strong financial position.
Analysts have pointed out the company’s improving financial performance, but they also caution about its dependence on limited suppliers and customers. Valiant Laboratories operates in the third-largest pharmaceutical API industry globally, contributing significantly to Paracetamol production, one of the most commonly used analgesics worldwide.
According to InvestingPro Tips, Valiant Laboratories is a prominent player in the Electrical Equipment industry, with a consistent increase in earnings per share. The company has also maintained dividend payments for 17 consecutive years, highlighting its commitment to shareholder returns.
Unistone Capital and Link Intime India managed the IPO of Valiant Laboratories. The listing represents a significant achievement for the company, as it navigates an intensely competitive market while maintaining a focus on a single product line.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here